Sugiura Fumiaki, Kojima Toshihisa, Oguchi Takeshi, Urata Shirou, Yuzawa Yukio, Sakakibara Akihiro, Hayashi Hiroki, Nishimoto Norihiro, Ishiguro Naoki
Department of Orthopedic Surgery, Anjo Kosei Hospital, 28 Higashihiroaze, Anjo-cho, Anjo, Aichi 466-8602, Japan.
Mod Rheumatol. 2009;19(2):199-203. doi: 10.1007/s10165-008-0132-2. Epub 2008 Nov 6.
We report a case of peripheral neuropathy and skin ulcer in a patient with rheumatoid arthritis (RA) who received tocilizumab. A 65-year-old woman with a 20-year history of RA participated in a tocilizumab clinical trial. She received a single dose of 8 mg/kg tocilizumab intravenously. The following day the patient started to experience numbness and purpura in all four extremities. The purpura of her left lower limb became necrotic, and a skin ulcer appeared 3 weeks later. Steroid-pulse treatment was initiated 12 weeks after tocilizumab administration, with the result that the numbness improved, and the skin ulcers showed complete epithelialization.
我们报告了1例接受托珠单抗治疗的类风湿关节炎(RA)患者出现周围神经病变和皮肤溃疡的病例。一名有20年RA病史的65岁女性参与了一项托珠单抗临床试验。她静脉注射了单剂量8 mg/kg的托珠单抗。次日,患者开始出现四肢麻木和紫癜。其左下肢紫癜发生坏死,3周后出现皮肤溃疡。在给予托珠单抗12周后开始进行类固醇冲击治疗,结果麻木症状改善,皮肤溃疡完全上皮化。